Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

When the study ended, weight loss did not plateau, suggesting that patients may continue to lose weight, Lilly said.

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Following the company’s announcement that its diabetes and weight-loss drug helped patients lose up to 16 pounds over 40 ...

We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Despite worries about an economic slowdown, Netflix continues to prove itself to be a recession-resistant stock.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to ...